Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

Introduction: EGFR mutations drive a subset of NSCLC. Patients harboring the common EGFR mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third-generation tyrosine kinase inhibitor. Nevertheless, the effect of osimertinib on NSCLC with atypical EGFR mutations is not well desc...

Full description

Bibliographic Details
Published in:JTO Clinical and Research Reports
Main Authors: Jingran Ji, MD, Jacqueline V. Aredo, MD, MS, Andrew Piper-Vallillo, MD, Laura Huppert, MD, Julia K. Rotow, MD, Hatim Husain, MD, Susan Stewart, PhD, Rosemary Cobb, BS, Heather A. Wakelee, MD, Collin M. Blakely, MD, PhD, Melisa L. Wong, MD, MAS, Matthew A. Gubens, MD, MS, Mohammad H. Madani, MD, Subba R. Digumarthy, MD, Caroline McCoach, MD, PhD, Zofia Piotrowska, MD, MHS, Joel W. Neal, MD, PhD, Jonathan W. Riess, MD, MS
Format: Article
Language:English
Published: Elsevier 2023-03-01
Subjects:
Osimertinib
Non–small cell lung cancer
Atypical EGFR mutation
L861Q
G719X
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001849

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001849

Similar Items